Table 3 Summary of new metastases by sitea based on independent review (intent-to-treat populations)
Parameter | Study 301 | Study 305/EMBRACE | ||
|---|---|---|---|---|
Eribulin | Capecitabine | Eribulin | TPC | |
(n = 554) | (n = 548) | (n = 508) | (n = 254) | |
Patients whose disease progressed owing to new metastases, n (%) | 216 (39.0 %) | 204 (37.2 %) | 139 (27.4 %) | 68 (26.8 %) |
Sites of new metastasesb, n (%) | ||||
Liver | 72 (33.3) | 80 (39.2) | 41 (29.5) | 30 (44.1) |
Lung | 30 (13.9) | 33 (16.2) | 8 (5.8) | 4 (5.9) |
Lymph nodes | 7 (3.2) | 3 (1.5) | 16 (11.5) | 6 (8.8) |
Bone | 19 (8.8) | 16 (7.8) | 7 (5.0) | 2 (2.9) |
Skin | 66 (30.6) | 62 (30.4) | 3 (2.2) | 1 (1.5) |
CNS (brain/spine) | 4 (1.9) | 17 (8.3) | 7 (5.0) | 0 |
Breast | 12 (5.6) | 7 (3.4) | 3 (2.2) | 0 |
Chest wall | 9 (4.2) | 4 (2.0) | 25 (18.0) | 5 (7.4) |
Other | 6 (2.8) | 13 (6.4) | 5 (3.6) | 4 (5.9) |